Baxalta Incorporated

Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets products for the treatment of hemophilia, immunology, and oncology. It provides products for the treatment of bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiencies, burns, shock, and other chronic and acute medical conditions, as well as acute lymphoblastic leukemia. The company offers ADVATE, a recombinant factor VIII therapy for the treatment of children and adults with hemophilia A; FEIBA, an inhibitor management therapy; and GAMMAGARD LIQUID, a liquid formulation of the antibody-replacement therapy for the treatment of primary immunodeficiency. Baxalta Incorporated was incorporated in 2014 and is based in Bannockburn, Illinois with additional offices in Zug, Switzerland; Westlake Village and Newbury Park, California; Lexington, Massachusetts; and Chicago, Illinois. Baxalta Incorporated operates as a subsidiary of Dyax Corp.